<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058028</url>
  </required_header>
  <id_info>
    <org_study_id>20170588</org_study_id>
    <nct_id>NCT04058028</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)</brief_title>
  <official_title>A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Rozibafusp Alfa (AMG 570) in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic&#xD;
      agent in the current treatment landscape where subjects with systemic lupus erythematosus&#xD;
      (SLE) have ongoing disease activity despite treatment with standard of care therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Bayesian adaptive phase 2b, multi-center, double-blind, randomized,&#xD;
      placebo-controlled, 52-week, dose-ranging study in subjects with active SLE and inadequate&#xD;
      response to SOC therapies including oral corticosteroids (OCS), immunosuppressants and&#xD;
      immunomodulators. Previous biologic use is allowed with an adequate washout period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">October 19, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 16, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a Bayesian adaptive phase 2b, multi-center, double-blind, randomized, placebo-controlled, 52-week, dose-ranging study in subjects with active systemic lupus erythematosus (SLE) and inadequate response to standard of care (SOC) therapies including oral corticosteroid (OCS), immunosuppressants, and immunomodulators. Subjects will be randomized to receive placebo or 1 of 3 doses of Rozibafusp Alfa with the last dose at week 50. Treatment will be administered every 2 weeks (Q2W). All subjects will be required to complete a 16-week follow-up period after the 52-week treatment period.&#xD;
The first interim analysis (IA) will be executed after the first 40 enrolled subjects have had the opportunity to complete the week 24 assessment. Additional IAs may be executed after approximately every 32 newly enrolled subjects have had the opportunity to complete the week 24 assessment. The last IA will occur when all subjects have had the opportunity to complete the week 24 assessment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients achieving Systemic Lupus Erythematosus Responder Index-4 (SRI-4) response at week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>SRI-4 response at Week 52 is defined as a greater than or equal to 4-point decrease in the hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score; no new British Isles Lupus Assessment Group (BILAG) 2004 A domain score and no greater than 1 new BILAG 2004 B scores compared with baseline; and a less than 0.3-point deterioration from baseline in Physician Global Assessment (PGA) (scale 0 to 3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of patients achieving a SRI-4 response at week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>SRI-4 response at Week 24 is defined as a greater than or equal to 4-point decrease in the hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score; no new British Isles Lupus Assessment Group (BILAG) 2004 A domain score and no greater than 1 new BILAG 2004 B scores compared with baseline; and a less than 0.3-point deterioration from baseline in Physician Global Assessment (PGA) (scale 0 to 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients achieving Lupus Low Disease Activity State (LLDAS) at week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>LLDAS response at week 52 is defined as a hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score ≤ 4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, and fever) and no haemolytic anaemia or gastrointestinal activity; no new findings of lupus disease activity compared with the previous assessment; ≤ 1-point in Physician Global Assessment (PGA) (scale 0 to 3) current prednisolone-equivalent dosage ≤ 7.5 mg/day; and standard maintenance dosages of immunosuppressive drugs and approved biologics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent on patients achieving The British Isles Lupus Assessment Group (BILAG) based Combined Lupus Assessment (BICLA) index responses</measure>
    <time_frame>Week 24 and Week 52</time_frame>
    <description>BICLA response is defined as at least 1 gradation of improvement in baseline BILAG domain scores in all body systems with moderate or severe disease activity at entry (eg, all A [severe disease] domain scores falling to B [moderate], C [mild], or D [no activity], and all B domain scores falling to C or D); no new BILAG 2004 A domain score and no greater than 1 new BILAG 2004 B domain scores compared with baseline; less than 0.3-point deterioration from baseline in Physician Global Assessment (PGA) (scale 0 to 3); and no initiation of non-protocol treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRI-4 at week 52 with reduction of OCS to less than or equal to 7.5 mg/day by week 44 and sustained through week 52 in subjects with a baseline OCS dose ≥ 10 mg/day</measure>
    <time_frame>week 52</time_frame>
    <description>To evaluate the efficacy of Rozibafusp Alfa with oral corticosteroid (OCS)-tapering in subjects with SLE with inadequate response to SOC therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized moderate and severe flare rate</measure>
    <time_frame>52 weeks</time_frame>
    <description>Measured by SELENA-SLEDAI Flare Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized severe flare rate</measure>
    <time_frame>52 weeks</time_frame>
    <description>Measured by SELENA-SLEDAI Flare Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized flare rate</measure>
    <time_frame>52 weeks</time_frame>
    <description>Measured by BILAG score designation of &quot;worse&quot; or &quot;new&quot; resulting in a B score in ≥ 2 organs or an A score in ≥ 1 organ) over 52 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total tender and swollen joint count ≥ 50% improvement from baseline at week 12, 24, 36, and 52 in subjects with ≥ 6 tender and swollen joints involving the hands and wrists at baseline</measure>
    <time_frame>Baseline, Week 12, 24, 36, and 52</time_frame>
    <description>A 28-joint count will be used to evaluate the effect of Rozibafusp Alfa on additional SLE efficacy endpoints. A total 28 joints will be scored for presence or absence of swelling. A separated score for joints in the hands and wrists will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cutaneous Lupus Erythematosus Area and Severity Index (CLASI) activity score ≥ 50% improvement from baseline at week 12, 24, 36, and 52 in subjects with a CLASI activity score ≥ 8 at baseline</measure>
    <time_frame>Baseline, Week 12, 24, 36, and 52</time_frame>
    <description>To evaluate the effect of Rozibafusp Alfa on additional SLE efficacy endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcome Measurement Information System Fatigue Short Form 7a Instrument (PROMIS-Fatigue SF7A) score change from baseline</measure>
    <time_frame>Baseline, Week 12, 24, 36, 44 and 52</time_frame>
    <description>To describe the effect of treatment with Rozibafusp Alfa using patient reported outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcomes Short Form 36 version 2 Questionnaire (SF36v2) score change from baseline</measure>
    <time_frame>Baseline, Week 12, 24, 36, 44 and 52</time_frame>
    <description>To describe the effect of treatment with Rozibafusp Alfa using patient reported outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lupus Quality of Life (QoL) score and change from baseline</measure>
    <time_frame>Baseline, Week 12, 24, 36, 44 and 52</time_frame>
    <description>To describe the effect of treatment with Rozibafusp Alfa using patient reported outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment (PtGA) score change from baseline</measure>
    <time_frame>Baseline, Week 12, 24, 36, 44 and 52</time_frame>
    <description>This is an 11-point NRS with 0 indicating lowest disease and 10 highest disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>52 weeks</time_frame>
    <description>To characterize the safety of Rozibafusp Alfa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject incidence of Serious adverse events</measure>
    <time_frame>52 weeks</time_frame>
    <description>To characterize the safety of Rozibafusp Alfa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with significant changes in laboratory values</measure>
    <time_frame>52 weeks</time_frame>
    <description>To characterize the safety of Rozibafusp Alfa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with significant changes in vital signs</measure>
    <time_frame>52 weeks</time_frame>
    <description>To characterize the safety of Rozibafusp Alfa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Rozibafusp Alfa trough concentrations</measure>
    <time_frame>52 Weeks</time_frame>
    <description>To characterize the pharmacokinetics (PK) of Rozibafusp Alfa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rozibafusp Alfa terminal elimination half-life, if possible</measure>
    <time_frame>52 weeks</time_frame>
    <description>To characterize the pharmacokinetics (PK) of Rozibafusp Alfa</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Systemic Lupus Erythematosus (SLE)</condition>
  <arm_group>
    <arm_group_label>Rozibafusp Alfa, Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational product solution in vial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rozibafusp Alfa, Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational product solution in vial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rozibafusp Alfa, Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational product solution in vial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Rozibafusp Alfa</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Investigational product solution in vial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rozibafusp Alfa</intervention_name>
    <description>Rozibafusp Alfa will be presented in 5 mL glass vial</description>
    <arm_group_label>Rozibafusp Alfa, Dose A</arm_group_label>
    <arm_group_label>Rozibafusp Alfa, Dose B</arm_group_label>
    <arm_group_label>Rozibafusp Alfa, Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Rozibafusp Alfa</intervention_name>
    <description>Placebo for Rozibafusp Alfa will be presented in 5 mL glass vial</description>
    <arm_group_label>Placebo for Rozibafusp Alfa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Screening Visit:&#xD;
&#xD;
          -  Subject has provided informed consent prior to initiation of any study-specific&#xD;
             activities/procedures.&#xD;
&#xD;
          -  Age ≥ 18 years to ≤ 75 years at screening visit.&#xD;
&#xD;
          -  Fulfills classification criteria for SLE according to the 2019 European League Against&#xD;
             Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for&#xD;
             SLE (Aringer et al, 2019), with antinuclear antibody ≥ 1:80 by immunofluorescence on&#xD;
             Hep-2 cells being present at screening.&#xD;
&#xD;
          -  Hybrid SLEDAI score ≥ 6 points with a &quot;Clinical&quot; hSLEDAI score ≥ 4 points. The&#xD;
             &quot;Clinical&quot; hSLEDAI is the hSLEDAI assessment score without the inclusion of points&#xD;
             attributable to laboratory results, including urine or immunologic parameters.&#xD;
&#xD;
        Additional protocol-specific rules are applied at screening and throughout the study, as&#xD;
        follows:&#xD;
&#xD;
          -  Arthritis: Arthritis (at least 3 tender and swollen joints) must involve joints in the&#xD;
             hands or wrists for the hSLEDAI scoring.&#xD;
&#xD;
          -  Alopecia: Subjects should have hair loss without scarring; should neither have&#xD;
             alopecia areata nor androgenic alopecia; and should have a CLASI activity score for&#xD;
             alopecia ≥ 2.&#xD;
&#xD;
          -  Oral ulcers: Ulcers location and appearance must be documented by the investigator.&#xD;
&#xD;
          -  Scleritis and Episcleritis: the presence of stable SLE-related scleritis and&#xD;
             episcleritis must be documented by an ophthalmologist and other causes excluded.&#xD;
&#xD;
          -  Renal: subjects with urine protein/creatinine ratio &lt; 3000 mg/g (or equivalent method)&#xD;
             in a clear catch spot urine sample can enroll and be scored in the hSLEDAI, provided&#xD;
             the subject has a clinical hSLEDAI ≥ 4 and did not receive induction treatment for&#xD;
             nephritis within the last year.&#xD;
&#xD;
          -  Pleurisy and Pericarditis: symptoms of pleurisy and pericarditis must be accompanied&#xD;
             by objective findings to be scored in the hSLEDAI.&#xD;
&#xD;
               -  Must be taking at least 1 but not more than 2 of the following SLE treatments&#xD;
                  unless there is a documented intolerance to the following treatments:&#xD;
                  anti-malarial (hydroxychloroquine, chloroquine, or quinacrine), azathioprine,&#xD;
                  methotrexate, mycophenolate mofetil/acid mycophenolic, or dapsone. Treatment&#xD;
                  should be taken for ≥12 weeks prior to screening and must be a stable dose for ≥&#xD;
                  8 weeks prior to screening. If subject is taking 2 of the above mentioned SLE&#xD;
                  treatments, 1 of these must be either hydroxychloroquine, quinacrine, or&#xD;
                  chloroquine.&#xD;
&#xD;
               -  For subjects taking OCS, dose must be ≤ 20 mg/day of prednisone or OCS&#xD;
                  equivalent, and the dose must be stable at baseline visit for ≥ 2 weeks prior to&#xD;
                  screening visit.&#xD;
&#xD;
        Exclusion Criteria Screening Visit&#xD;
&#xD;
        Subjects are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
        Disease Related&#xD;
&#xD;
          -  Urine protein creatinine ratio ≥ 3000 mg/g (or equivalent) at screening or induction&#xD;
             therapy for lupus nephritis within 1 year prior to screening visit.&#xD;
&#xD;
          -  Active CNS lupus within 1 year prior to screening including, but not limited to,&#xD;
             aseptic meningitis, ataxia, CNS vasculitis, cranial neuropathy, demyelinating&#xD;
             syndrome, optic neuritis, psychosis, seizures, or transverse myelitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imaging Endpoints</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91722</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TriWest Research Associates</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>Fontana</city>
        <state>California</state>
        <zip>92335</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre for Rheumatology Immunology and Arthritis</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heuer Medical Doctor Research LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southwest Florida Clinical Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Medical Group</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Piedmont Atlanta Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinic of Robert Hozman, MD - Clinical Investigational Specialists, Inc</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine Division of Rheumatology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Feinstein Institute for Medical Research</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York University Langone Orthopedic Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital For Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Joint and Muscle Research Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research PLLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatology Center of Oklahoma PLLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Oklahoma Center for Arthritis Therapy and Research Inc</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn State Milton South Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Articularis Healthcare Group Inc dba Low Country Rheumatology</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Regional Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trinity Universal Research Associates, Inc</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Clinical Research Center LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Southwest Rheumatology</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dom Centro de Reumatologia</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1111AAJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Respirar - Centro Medico Dra De Salvo</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas Quilmes</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>B1878GEG</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Medico de Alta Complejidad San Isidro</name>
      <address>
        <city>San Isidro</city>
        <state>Buenos Aires</state>
        <zip>1642</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Militar Central - Cirujano Mayor Dr Cosme Argerich</name>
      <address>
        <city>Buenos Aires</city>
        <state>Distrito Federal</state>
        <zip>C1426BOR</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Mayo - Clinica Mayo de Urgencias Medicas Cruz Blanca S.R.L</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado de Reumatologia</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CER San Juan - Centro Polivalente de Asistencia e Investigacion Clinica</name>
      <address>
        <city>San Juan</city>
        <zip>5400</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Trimontium OOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment - Kaspela EOOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Sveti Georgi EAD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Excelsior OOD</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Academy EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Centre Synexus Sofia EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Centre Synexus Sofia EOOD - Branch Stara Zagora</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Calgary Cumming School of Medicine</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shared Health Inc. operating the Health Sciences Centre Winnipeg</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe de recherche en maladies osseuses Incorporated</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Czech sro</name>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux - Hopital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre</name>
      <address>
        <city>Caen Cedex 9</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Dijon Bourgogne - Hopital Francois Mitterrand</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille cedex 01</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Strasbourg - Nouvel hopital civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse - Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz</name>
      <address>
        <city>Bad Kreuznach</city>
        <zip>55543</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laiko General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano MI</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Chibahigashi National Hospital</name>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <zip>260-8712</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Occupational and Environmental Health</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <zip>807-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sapporo City General Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-8604</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa-shi</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National University Corporation Tohoku University Tohoku University Hospital</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki-shi</city>
        <state>Nagasaki</state>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagasaki Medical Center</name>
      <address>
        <city>Omura-shi</city>
        <state>Nagasaki</state>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sasebo Chuo Hospital</name>
      <address>
        <city>Sasebo-shi</city>
        <state>Nagasaki</state>
        <zip>857-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurashiki Medical Clinic</name>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama</state>
        <zip>710-0824</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seirei Hamamatsu General Hospital</name>
      <address>
        <city>Hamamatsu-shi</city>
        <state>Shizuoka</state>
        <zip>430-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Lukes International Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Tokyo Medical Center</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07985</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon-si, Gyeonggi-do</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Medico del Angel SC</name>
      <address>
        <city>Mexicali</city>
        <state>Baja California Norte</state>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Artritis y Osteoporosis SC</name>
      <address>
        <city>Mexicali</city>
        <state>Baja California Norte</state>
        <zip>21200</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Morales Vargas Centro de Investigacion SC</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Integral en Reumatologia SA de CV</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Peninsular de Investigación Clínica</name>
      <address>
        <city>Merida</city>
        <state>Yucatán</state>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Spzoo</name>
      <address>
        <city>Gdansk</city>
        <zip>80-382</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Spzoo</name>
      <address>
        <city>Gdynia</city>
        <zip>81-537</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Spzoo</name>
      <address>
        <city>Katowice</city>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Silmedic Spzoo</name>
      <address>
        <city>Katowice</city>
        <zip>40-282</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tomed Tomasz Miszalski-Jamka Centrum Medyczne</name>
      <address>
        <city>Krakow</city>
        <zip>31-209</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Spzoo</name>
      <address>
        <city>Lodz</city>
        <zip>90-127</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SOMED CR</name>
      <address>
        <city>Lodz</city>
        <zip>90-368</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1 Wojskowy Szpital Kliniczny z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej</name>
      <address>
        <city>Lublin</city>
        <zip>20-049</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Best Solutions Spolka z ograniczona odpowiedzialnoscia Spolka komandytowa</name>
      <address>
        <city>Lublin</city>
        <zip>20-078</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Spzoo</name>
      <address>
        <city>Poznan</city>
        <zip>60-702</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanus Szpital Specjalistyczny Spzoo</name>
      <address>
        <city>Stalowa Wola</city>
        <zip>37-450</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Spzoo</name>
      <address>
        <city>Warszawa</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SOMED CR</name>
      <address>
        <city>Warszawa</city>
        <zip>01-737</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Futuremeds spolka z ograniczona odpowiedzialnoscia</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Spzoo</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-381</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Garcia de Orta, EPE</name>
      <address>
        <city>Almada</city>
        <zip>2801-951</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Ocidental, EPE - Hospital Egas Moniz</name>
      <address>
        <city>Lisboa</city>
        <zip>1349-019</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto EPE - Hospital de Santo Antonio</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universtario de Sao Joao, EPE</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Budget Medical Institution Sverdlovsk Regional Clinical Hospital N1</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Limited liability company Scientific Research Medical Complex Your Health</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC Medical Center Maksimum Zdorovia</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC Medical center Revma Med</name>
      <address>
        <city>Kemerovo</city>
        <zip>650070</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSBSI SRI of Rheumatology na V A Nasonova</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC Center of medicine Healthy family</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630061</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC Center of general medicine</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC Medical Sanitary Unit №157</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 30, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Standard of Care therapies</keyword>
  <keyword>Oral Corticosteroids</keyword>
  <keyword>Inmunosuppressants</keyword>
  <keyword>Inmunodulators</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>B cell Activating Factor (BAFF)</keyword>
  <keyword>Inducible T cell costimulator ligand (ICOSL)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

